Divozilimab

BIOLOGICAL4 trials

Sponsors

Biocad

Conditions

Multiple SclerosisNeuromyelitis Optica Spectrum DisordersSystemic Lupus ErthematosusSystemic Scleroderma

Phase 1

Safety, Pharmacokinetics, Immunogenicity BCD-256-1 and Divozilimab in Subjects With Systemic Lupus Erythematosus

RecruitingNCT07136389

BiocadSystemic Lupus Erthematosus

Start: 2025-03-27End: 2026-11-01Target: 135Updated: 2025-08-22

Phase 3

Clinical Study of Divozilimab in Patients With Systemic Scleroderma

Active, not recruitingNCT05726630

BiocadSystemic Scleroderma

Start: 2022-12-26End: 2027-02-01Updated: 2026-06-10

Efficacy and Safety of Divozilimab in Patients With Neuromyelitis Optica Spectrum Disorders (AQUARELLE)

Active, not recruitingNCT05730699

BiocadNeuromyelitis Optica Spectrum Disorders

Start: 2022-12-12End: 2026-09-30Target: 105Updated: 2024-11-07

An Extension Clinical Study of the Efficacy and Safety of BCD-132 in Patients With Multiple Sclerosis Who Previously Received Therapy in Clinical Studies of JSC BIOCAD

CompletedNCT06987851

BiocadMultiple Sclerosis

Start: 2022-03-22End: 2024-05-16Updated: 2025-05-23

Related Papers

Divozilimab in neuromyelitis optica spectrum disorders: Evidence-based consensus of Russian committees of experts and clinical potential

Meditsinskiy sovet = Medical Council2026-08-24